Page 100 - Aet News Today

Dementia patients require a balanced blend of supportive devices, effective medications such as cholinesterase inhibitors and holistic understanding to truly enjoy the best possible quality of life.

Viome Life Sciences' Series C funding round included participation from Khosla Ventures, Bold Capital and WRG Ventures. In total, Viome has raised $175 million.

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.

Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.

Telehealth Academy III, a conference exploring the virtual care delivery landscape, will be one of the highlights of an inaugural week of events organized in the healthcare provider hub of Nashville, referred to as Nashville Healthcare Sessions.

While we’re catching a high-risk population through preventive screenings, we are also identifying an entirely separate high-risk population: children of the patients that were just screened and found to have high risk polyps such as greater than 1 cm or with certain advanced characteristics.

Generic drugmakers Teva and Glenmark recently became the sixth and seventh drugmakers to resolve criminal charges as a result of the DOJ’s yearslong investigation into generic drug price fixing. The settlement agreement requires both companies to pay hefty fines as well as divest their drug lines for pravastatin, a widely used statin that lowers cholesterol.

Pharmaceutical manufacturers say high U.S. prices support research and development and point out that Americans tend to get new treatments first. But recent research has shown that the price of a drug is related neither to the amount of research and development required to bring it to market nor its therapeutic value.

The current imaging interpretation model undoubtedly has reached its breaking point due to increasing volumes and fewer radiologists. The time is now to solve this systemic imaging interpretation issue.

Employer-sponsored health insurance now costs approximately $12,000 per plan member per year. Accordingly, for many employers, healthcare and health insurance are the second largest company expense after payroll. The Head of Benefits is in charge of this expense and is in the best position to use it for positive change.